{"filing":{"accession_number":"0000875320-26-000278","cik":"0000875320","ticker":"VRTX","company_name":"VERTEX PHARMACEUTICALS INC / MA","form":"8-K","filing_date":"2026-10-20","report_date":"2026-10-20","primary_document":"vrtx-20261020.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000278/vrtx-20261020.htm"},"events":[{"id":36409,"run_id":33574,"accession_number":"0000875320-26-000278","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Daniel Brennan was appointed as a new member of the board of directors of Vertex Pharmaceuticals on October 20, 2026, with the board size increasing from ten to eleven members. While the disclosure also mentions a $400,000 restricted stock unit award, the principal disclosed action is the appointment itself. Brennan's extensive finance and healthcare background (former CFO of Boston Scientific, current board member at Waters and Madrigal Pharmaceuticals) and his assignment to the Audit and Finance Committee make this a material governance event affecting investor assessment of board composition and oversight.","company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","filing_date":"2026-10-20","form":"8-K","submitted_at":null,"items":[{"id":40818,"accession_number":"0000875320-26-000278","item_number":"5.02","item_title":"Departure of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Daniel Brennan was appointed as a new member of the board of directors of Vertex Pharmaceuticals on October 20, 2026, with the board size increasing from ten to eleven members. While the disclosure also mentions a $400,000 restricted stock unit award, the principal disclosed action is the appointment itself. Brennan's extensive finance and healthcare background (former CFO of Boston Scientific, current board member at Waters and Madrigal Pharmaceuticals) and his assignment to the Audit and Finance Committee make this a material governance event affecting investor assessment of board composition and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T20:11:37.203593+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40818,"accession_number":"0000875320-26-000278","item_number":"5.02","item_title":"Departure of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Daniel Brennan was appointed as a new member of the board of directors of Vertex Pharmaceuticals on October 20, 2026, with the board size increasing from ten to eleven members. While the disclosure also mentions a $400,000 restricted stock unit award, the principal disclosed action is the appointment itself. Brennan's extensive finance and healthcare background (former CFO of Boston Scientific, current board member at Waters and Madrigal Pharmaceuticals) and his assignment to the Audit and Finance Committee make this a material governance event affecting investor assessment of board composition and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T20:11:37.203593+00:00","company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","filing_date":"2026-10-20"}]}